OpGen Inc (OPGN)

[chillswills37]

$OPGN Why is bioMérieux's acquisition bullish for OpGen? There are meaningful parallels, perhaps foreshadowings, as they relate to OpGen's collaborators such as Sandoz, Merck, et alii.

French firm bioMérieux (2021 revenue US$3.82B) is an in vitro diagnostics biotechnology firm whose history traces back to Louis Pasteur. April 12, 2022: bioMérieux announces agreement to acquire Specific Diagnostics (SD), private U.S. based firm, developer of rapid antimicrobial susceptibility test (AST) system delivering phenotypic AST directly from positive blood cultures.(Note: SD system CE marked; not US-FDA approved; RUO) bioMérieux CEO says their 'acquisition reinforces commitment to sustain antibiotic efficacy for future generations.'

The CEO Richard Sayno of Sandoz, world's leading provider of generic antibiotics, said much the same thing about Sandoz's "key" collaboration with OpGen --except he knows, as is evident by his remarks, that OpGen biotech scores more points than Specific Diagnostics' AST given OpGen's far more robust system, FDA Approved, and AI-powered bioinformatics solutions for antibiotic response prediction, to boot.

Sandoz CEO Richard Saynor stated, “Antibiotics are the cornerstone of modern medicine. AMR, which is now estimated to directly account for nearly 1.3 million deaths worldwide every year, is an unprecedented threat to global public health. As the world’s leading provider of generic antibiotics, our goal at Sandoz is to play a key role in overcoming this growing threat. This collaboration (w/OpGen sub) is a key step towards that goal, allowing us to take the fight directly to AMR by using cutting-edge big data and AI approaches combined with traditional data sets. By combining our respective skillsets, we believe we can not only use diagnostic and surveillance data to help healthcare professionals make better diagnoses, but also expand our options to treat AMR in the future, by targeted repurposing of key antibiotics. Our ultimate goal is both simple and radical: to ensure we get the right medicine to the right patient at the right time.”

https://www.globenewswire.com/news-release/2022/04/06/2417469/35690/en/OpGen-s-subsidiary-Ares-Genetics-provides-update-on-collaboration-agreement-to-drive-cutting-edge-digital-solutions-in-global-fight-against-antimicrobial-resistance-AMR.html